WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015095834) CANCER TREATMENTS USING ERK1/2 AND BCL-2 FAMILY INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/095834    International Application No.:    PCT/US2014/071736
Publication Date: 25.06.2015 International Filing Date: 19.12.2014
IPC:
A61K 31/5377 (2006.01), A61K 31/4412 (2006.01), A61K 31/166 (2006.01), A61K 31/352 (2006.01), A61K 31/277 (2006.01), A61K 31/444 (2006.01)
Applicants: BIOMED VALLEY DISCOVERIES, INC. [US/US]; 4520 Main Street, 16th Fl. Kansas City, MO 64111 (US)
Inventors: SAHA, Saurabh; (US).
WELSCH, Dean; (US).
DECRESCENZO, Gary; (US).
ROIX, Jeffrey, James; (US)
Agent: HOOPER, Kevin; (US)
Priority Data:
61/919,148 20.12.2013 US
Title (EN) CANCER TREATMENTS USING ERK1/2 AND BCL-2 FAMILY INHIBITORS
(FR) TRAITEMENTS DU CANCER FAISANT APPEL À DES INHIBITEURS DES FAMILLES ERK1/2 ET BCL-2
Abstract: front page image
(EN)The present invention provides, inter alia, methods for treating or ameliorating the effects of a cancer in a subject in need thereof. These methods include administering to the subject an effective amount of (i) an ERK1/2 inhibitor (such as BVD-523) or a pharmaceutically acceptable salt thereof and (ii) a BCL-2 family inhibitor (such as navitoclax) or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Kits and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject and methods for selecting a subject with cancer that may benefit from a combination drug therapy are also provided.
(FR)La présente invention concerne, inter alia, des méthodes pour le traitement ou l'amélioration des effets d'un cancer chez un sujet qui a besoin d'un tel traitement. Ces méthodes consistent à administrer au sujet une quantité efficace de (i) un inhibiteur de l'ERK1/2 (tel que le BVD-523) ou son sel pharmaceutiquement acceptable, et (ii) un inhibiteur de la famille BCL-2 (tel que le navitoclax) ou son sel pharmaceutiquement acceptable, pour traiter ou améliorer les effets du cancer. L'invention concerne également des kits et des compositions pharmaceutiques pour le traitement ou l'amélioration des effets d'un cancer chez un sujet et des méthodes permettant de sélectionner un sujet atteint d'un cancer qui pourrait bénéficier d'une pharmacothérapie comprenant une association médicamenteuse.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)